Company is pleased to announce that USFDA has concluded that their inspection is "closed" under 21 CFR 20.64(d)(3). With the above audit closure confirmation received from the USFDA, ....

Regulatory product approvalBusiness Updates View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.0%Reaction day

₹12.69

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.2%+0.8% vs market

Pharmaceuticals peers, median of 150sector+1.0%+1.0% vs sector

On the reaction day the stock moved 0.8 pts more than Nifty Microcap 250 and 1.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.0+1.2+0.8+1.0+1.0

Next day

+3.9+0.1+3.8-0.2+4.1

+6.0+0.9+5.1+0.5+5.4

+8.0+0.8+7.3+0.1+8.0

+10.2+1.4+8.7+0.1+10.0

+15.6+2.0+13.6+0.5+15.1

+19.5+2.3+17.3+1.5+18.1

15d

+29.8+5.2+24.6+1.4+28.3

+40.7+1.6+39.1-1.5+42.2

+72.2+7.7+64.5+3.5+68.7

+71.4+4.0+67.4-0.5+71.9

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 150Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Veerhealth Care Ltd announced on 16th May 2025 that the USFDA has formally concluded its inspection as 'closed' under 21 CFR 20.64(d)(3). With this regulatory clearance, the company is now fully qualified to export its oral care products to the USA market. The company's manufacturing facility is located in Vapi, Gujarat. This marks a key compliance milestone that removes a regulatory hurdle for entering the US market.

Likely market impact

Positive for shareholders — USFDA clearance opens the door to the large US oral care market, which could support future revenue growth and export earnings, though no specific order or revenue guidance has been announced yet.